atorvastatin has been researched along with exenatide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Philips, JC; Radermecker, RP; Scheen, AJ | 1 |
| Bijjem, KV; Goyal, S; Kumar, S; Singh, M | 1 |
| Basiak, M; Boldys, A; Buldak, L; Buldak, RJ; Kosowski, M; Machnik, G; Maliglowka, M; Okopien, B; Skudrzyk, E | 1 |
1 review(s) available for atorvastatin and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for atorvastatin and exenatide
| Article | Year |
|---|---|
[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Protein Precursors; Pyrroles; Venoms | 2004 |
Role of glucagon-like peptide- 1 in vascular endothelial dysfunction.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Endothelium, Vascular; Exenatide; Female; Glucagon-Like Peptide 1; Heptanoic Acids; Hyperhomocysteinemia; In Vitro Techniques; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Peptides; Pyrroles; Rats; Rats, Wistar; Venoms | 2010 |
Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner.
Topics: Atorvastatin; Cyclic AMP-Dependent Protein Kinases; Exenatide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Proprotein Convertase 9; Receptors, LDL | 2022 |